JP Morgan Chase’s Akebia Therapeutics AKBA Stock Holding History

JP Morgan Chase’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,000,000	Closed	-$2.8M	–	6025
2020 Q4	$2.8M	Hold	1,000,000	–	–	﹤0.01%	3246
2020 Q3	$2.39M	Hold	1,000,000	–	–	﹤0.01%	3120
2020 Q2	$13.6M	Hold	1,000,000	–	–	﹤0.01%	1668
2020 Q1	$7.58M	Buy	1,000,000 +500,000	+100%	+$3.89M	﹤0.01%	1945
2019 Q4	$3.16M	Sell	500,000 -1,990,000	-80%	-$9.46M	﹤0.01%	3054
2019 Q3	$9.76M	Hold	2,490,000	–	–	﹤0.01%	2150
2019 Q2	$11.5M	Buy	+2,490,000	New	+$14.2M	﹤0.01%	1988
2019 Q1	–	Sell	-5,000	Closed	-$28K	–	5738
2018 Q4	$28K	Hold	5,000	–	–	﹤0.01%	5248
2018 Q3	$44K	Hold	5,000	–	–	﹤0.01%	5241
2018 Q2	$50K	Buy	+5,000	New	+$50.1K	﹤0.01%	5077

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase's AKBA Position: Q1 2026 in Review

JP Morgan Chase reduced its Akebia Therapeutics (AKBA) stake by 41% in Q1 2026, selling an estimated $110K and leaving 114,047 shares worth $151K. The position accounts for ﹤0.01% of the portfolio, ranked #5619.

JP Morgan Chase first reported a position in AKBA in Q4 2015 and has held it in 39 quarters since. The position peaked at $18.8M in Q2 2021. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

JP Morgan Chase held 114,047 shares of Akebia Therapeutics worth $151K as of Q1 2026.
JP Morgan Chase sold 79,979 Akebia Therapeutics shares in Q1 2026, an estimated $110K.
Akebia Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5619 holding.
JP Morgan Chase first reported a position in Akebia Therapeutics in Q4 2015 and has held it in 39 quarters since.
JP Morgan Chase's Akebia Therapeutics position peaked at $18.8M in Q2 2021.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.